Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies

Jang, Bora; Kwon, Hyokyoung; Katila, Pramila; Lee, Seung Jin; Lee, Hyukjin

doi:10.1016/j.addr.2015.10.023

Cited by 92 publications

(54 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides the potential role of HSP inhibition in overcoming the multidrug resistances, some groups focused their research on the development of strategies involving combination therapies, inhibition of the drug efflux pumps, and of ABC cassettes [7][8][9] . Combination therapies are more and more developed as standard of care for resistant cancers: example include RVD (Lenalidomide (immunomodulatory drug), Bortezomib (proteasome inhibitor), Dexamethasone (glucocorticoid)) for relapsed multiple myeloma, CAF (Cyclophosphamide, Adriamycin and fluorouracil) for metastatic breast cancer or BEP (Bleomycin, etoposide phosphate, cisplatin) for ovarian malignant cancer, … Several principles must be considered while setting up a strategy for combination therapies [10] .…”

Section: Drug Delivery Systems the Way To Overcome Cancer Resistancementioning

confidence: 99%

Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Mathieu¹,

Messaoudi²,

Fattal³

et al. 2019

CDR

View full text Add to dashboard Cite

Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using Hsp90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of Hsp90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells.

show abstract

Section: Drug Delivery Systems the Way To Overcome Cancer Resistancementioning

confidence: 99%

Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Mathieu¹,

Messaoudi²,

Fattal³

et al. 2019

CDR

View full text Add to dashboard Cite

show abstract

“…This also helped to develop several biological therapies that have rapidly entered the market and are now available for both cancer and inflammatory disease, such as somatostatin, estrogen analogues, hormone receptor monoclonal antibodies (mAbs), growth factor inhibitors, cytokines, chemokines, tyrosine kinase inhibitors, etc [4]. All of these are able to interfere with the different pathways by binding key signalling molecules.…”

Section: Introductionmentioning

confidence: 99%

Immunoscintigraphy for Therapy Decision Making and Follow - Up of Biological Therapies

Galli¹

2016

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets. In this scenario nuclear medicine offers many radiopharmaceuticals for SPECT or PET imaging of many pathological conditions. The availability of monoclonal antibodies provides tools to target specific antigens involved in angiogenesis, cell cycle or modulation of the immune systems. The radiolabelling of such therapeutic mAbs is a promising method to evaluate the antigenic status of each cancer lesion or inflamed sites before starting the therapy. It may also allow to perform follow-up of such biological therapies. In the present review we provide an overview of the most studied radiolabelled antibodies for therapy decision making and follow-up of patients affected by cancer and other pathological conditions.

show abstract

“…71 Combinations of drugs can have a synergistic effect, providing better treatment outcomes than single drug therapy. [71][72][73] As mentioned earlier, platinum compounds are combined commonly with other anticancer agents including fluorouracil, etoposide, paclitaxel, and capecitabin. 74 However, the successful simultaneous administration of two anticancer agents can be difficult due to the differences in drug solubility, biodistribution, and pharmacokinetics.…”

Section: Simultaneous Incorporation and Delivery Of Other Anticancer mentioning

confidence: 99%

Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma

et al. 2016

View full text Add to dashboard Cite

Glioblastoma (GBM) is a fatal brain cancer for which new treatment options are sorely needed. Platinumbased drugs have been investigated extensively for GBM treatment but few have shown significant efficacy without major central nervous system (CNS) and systemic toxicities. The relative success of platinum drugs for treatment of non-CNS cancers indicates great therapeutic potential when effectively delivered to the tumor region(s). New insights into the broad anticancer effects of platinum drugs, particularly immunomodulatory effects, and innovative delivery strategies that can maximize these multimodal effects and minimize toxicities may promote the re-purposing of this chemotherapeutic drug class for GBM treatment.

show abstract

Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies

Cited by 92 publications

References 135 publications

Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Immunoscintigraphy for Therapy Decision Making and Follow - Up of Biological Therapies

Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma

Contact Info

Product

Resources

About